![Adriaan Moelker Manfred Bender BRAIN AG Annual General Meeting FY 2018/2019](https://www.brain-biotech.com/sized/images/News/10404287/Adriaan-Moelker_Manfred-Bender_BRAIN-AG-Hauptversammlung-GJ-2018_2019_web_low-res_2bbeabe1db4886ca591241016e88b120.jpeg 1000w 425h, https://www.brain-biotech.com/sized/images/News/10404287/Adriaan-Moelker_Manfred-Bender_BRAIN-AG-Hauptversammlung-GJ-2018_2019_web_low-res_231ca0c0d969e772beddb7342acec814.jpeg 992w 422h, https://www.brain-biotech.com/sized/images/News/10404287/Adriaan-Moelker_Manfred-Bender_BRAIN-AG-Hauptversammlung-GJ-2018_2019_web_low-res_4837ca9b07a5bbff420749be557f3e05.jpeg 768w 327h, https://www.brain-biotech.com/sized/images/News/10404287/Adriaan-Moelker_Manfred-Bender_BRAIN-AG-Hauptversammlung-GJ-2018_2019_web_low-res_831950fdf54cee73292dc93f41f24517.jpeg 576w 245h, https://www.brain-biotech.com/sized/images/News/10404287/Adriaan-Moelker_Manfred-Bender_BRAIN-AG-Hauptversammlung-GJ-2018_2019_web_low-res_40f6dcd4901a231b8e31e9108f8a98bb.jpeg 400w 170h)
Just in time: Annual general meeting FY 2018/19
The invitation to the Annual General Meeting of BRAIN AG in March 2020 was accepted by many shareholders, despite the fact that the corona crisis had already been announced. Attendance, measured by share capital, was around 70%.
Many bottles of disinfectant were standing ready and waiting when the first shareholders of BRAIN AG entered the Melibokushalle in Zwingenberg, Germany, this year. What was still allowed on 5 March would not have been acceptable a week later. Three days earlier, the Robert Koch Institute had raised its risk assessment for Germany from "low to moderate" to "moderate" and a week later the "lockdown" in Germany began.
Those who had come followed the meeting attentively and exercised their voting rights. Thus, with the exception of one item, the agenda items were accepted by the participating shareholders.
Manfred Bender, CFO on the Management Board of BRAIN AG, explained and summarized the figures for the past financial year: “We have clearly achieved our goal of double-digit growth. This is a remarkable development in the general economic environment.”
The shareholders re-elected Dr. Georg Kellinghusen to the Supervisory Board by a large majority. Kellinghusen planned to stand for re-election as Chairman at the constituent meeting of the Supervisory Board.
“We have clearly achieved our goal of double-digit growth. This is a remarkable development in the general economic environment.”
![BRAIN Annual General Meeting FY 2018/2019](https://www.brain-biotech.com/sized/images/News/10404468/BRAIN_HV_1_11ce62e385c972e24f0bebc3693c244f.jpg 1480w 980h, https://www.brain-biotech.com/sized/images/News/10404468/BRAIN_HV_1_4da8cb0eaa173ff04e41c327fffd2035.jpg 1216w 805h, https://www.brain-biotech.com/sized/images/News/10404468/BRAIN_HV_1_4425464adce20ef68230266fdd385714.jpg 992w 656h, https://www.brain-biotech.com/sized/images/News/10404468/BRAIN_HV_1_9ec1789f949db491650ab0f5be3d76b6.jpg 768w 508h, https://www.brain-biotech.com/sized/images/News/10404468/BRAIN_HV_1_a684d3096d988b4015570ba64e80e48a.jpg 576w 381h, https://www.brain-biotech.com/sized/images/News/10404468/BRAIN_HV_1_3277e6d2c75216156f4e94fa1318b1b6.jpg 400w 264h)
It is currently still open in which form the AGM in 2021 for the 2019/20 financial year of BRAIN AG will take place - whether purely virtual, face-to-face or as a hybrid of both. What is certain, however, is that listed companies must be prepared for all eventualities in the future.
The detailed voting results as well as the presentation of the Management Board and all other documents relating to the Annual General Meeting can be found on the BRAIN AG website.
![](https://www.brain-biotech.com/sized/images/News/10404554/HV_2_11ce62e385c972e24f0bebc3693c244f.jpg 1480w 986h, https://www.brain-biotech.com/sized/images/News/10404554/HV_2_4da8cb0eaa173ff04e41c327fffd2035.jpg 1216w 810h, https://www.brain-biotech.com/sized/images/News/10404554/HV_2_4425464adce20ef68230266fdd385714.jpg 992w 661h, https://www.brain-biotech.com/sized/images/News/10404554/HV_2_9ec1789f949db491650ab0f5be3d76b6.jpg 768w 512h, https://www.brain-biotech.com/sized/images/News/10404554/HV_2_a684d3096d988b4015570ba64e80e48a.jpg 576w 384h, https://www.brain-biotech.com/sized/images/News/10404554/HV_2_3277e6d2c75216156f4e94fa1318b1b6.jpg 400w 266h)